AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
+0.29 (4.54%)
Real-time:   11:29AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.29 - 6.72
52 week 5.22 - 13.64
Open 6.38
Vol / Avg. 199,714.00/504,593.00
Mkt cap 291.97M
P/E     -
Div/yield     -
EPS -0.04
Shares 43.71M
Beta 1.93
Inst. own 81%
Mar 2, 2015
Q4 2014 AcelRx Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
AcelRx Pharmaceuticals Inc at Roth Utah Corporate Access Event
Dec 4, 2014
AcelRx Pharmaceuticals Inc at RBC Capital Markets Denver Healthcare Investor Day
Dec 2, 2014
AcelRx Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 19, 2014
AcelRx Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London
Nov 11, 2014
AcelRx Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 10, 2014
Q3 2014 AcelRx Pharmaceuticals Inc Earnings Call - Webcast
Nov 10, 2014
Q3 2014 AcelRx Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 13.91% -79.40%
Operating margin -105.06% -22.60%
EBITD margin - -20.59%
Return on average assets 2.73% -26.84%
Return on average equity 4.70% -43.78%
Employees 27 -
CDP Score - -


351 Galveston Drive
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company's products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Richard A. King President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 51
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 50
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 62
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 60
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 56
Bio & Compensation  - Reuters
Stephen J. Hoffman M.D. Ph.D. Independent Director
Bio & Compensation  - Reuters
Howard B. Rosen Independent Director
Age: 55
Bio & Compensation  - Reuters